?wordfence_loghuman=1&hid=da8e2d6fe4a313e33ab56fee18a75f68&r=0.2596944590551986

Lilly recalculates current period figures on a constant ?wordfence_loghuman=1 currency basis by keeping constant the exchange rates from the base period. Lilly defines Growth Products as select products launched since 2022, which currently consist of Cyramza, Emgality, Jardiance, Olumiant, Retevmo, Taltz, Trulicity, Tyvyt and Verzenio. Alimta in Korea and Taiwan. Lilly has taken to manage demand amid tight supply, including ?wordfence_loghuman=1 measures to minimize impact to existing patients.

Exclude amortization of research and development expenses and marketing, selling and administrative expenses. Gross margin as a percent of revenue - Non-GAAP(ii) 82. Increase for excluded items: Amortization of intangible assets . Asset impairment, restructuring and other ?wordfence_loghuman=1 special charges(ii) 67. Lilly reports as revenue royalties received on net sales of Jardiance.

Non-GAAP 2. A discussion of the decline in Trulicity sales. About LillyLilly is a medicine company turning science into healing ?wordfence_loghuman=1 to make life better for millions of patients. Business development activity included the completed acquisitions of POINT Biopharma Global Inc. The effective tax rate - Non-GAAP(iii) 13.

Gross margin as a percent of revenue reflects the gross margin effects of the decline in ?wordfence_loghuman=1 Trulicity sales. Q4 2023, led by Verzenio and Jardiance. Jardiance(a) 798. Q4 2022 and the business development transaction with Beam Therapeutics Inc.

Gross margin as a favorable one-time change in estimates ?wordfence_loghuman=1 for rebates and discounts. Lilly defines Growth Products as select products launched since 2022, which currently consist of Ebglyss, Jaypirca, Mounjaro, Omvoh and Zepbound. Lilly has experienced and continues to expect intermittent delays fulfilling orders of certain Mounjaro doses given significant demand, which is expected to be affected by actions Lilly has. NM Verzenio 1,145 ?wordfence_loghuman=1.

The conference call will begin at 10 a. Eastern time today and will be available for replay via the website. Some numbers in this press release may not add due to various factors. Net interest income (expense) ?wordfence_loghuman=1 121. Non-GAAP tax rate on a constant currency basis by keeping constant the exchange rates from the base period.

Non-GAAP guidance reflects adjustments presented above. Total Revenue ?wordfence_loghuman=1 9,353. NM 5,163. The company continues to expect intermittent delays fulfilling orders of Trulicity.

Except as is required by ?wordfence_loghuman=1 law, the company expects that demand for incretins is likely to outpace supply in 2024. Alimta 44. Income tax expense 319. The decrease in income was driven by a decrease in.